Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CEST

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at djnews.frankfurt@dowjones.com

Stocks mentioned in the article : Merck KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
08:11a MERCK : Darmstadt, Germany Advances R&D Strategy through Unique Development Mode..
03/28 PFIZER : FDA Approves PD-L1 Immunotherapy Developed by Pfizer and Merck KGaA
03/25 Merck KGaA and Pfizer break into cancer immunotherapy
03/25 Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy Bavencio
03/24 MERCK : Global Analyzer for Particle Counters Market- HCT Instruments, Honri, IQ..
03/23 MERCK : FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Ap..
03/23 PFIZER : FDA Grants Approval for BAVENCIO (avelumab), the First Immunotherapy Ap..
03/23 PFIZER : FDA Grants Approval for BAVENCIO (avelumab)
03/22 “BOLD & VIBRANT” : Merck KGaA, Darmstadt, Germany, Presents Innovati..
03/22 MERCK : unveils 2017 Darmstadt and Nairobi accelerator startups
More news
Sector news : Specialty & Advanced Pharmaceuticals
11:07aDJOXFORD BIOMEDICA : Hails U.S. Regulatory Boost for Leukemia Treatment
03/29 FDA, Mylan silence on generic Advair may be good news for GSK
03/29 British business navigates rocky path to Brexit
03/29 ConvaTec's majority investors raise $1.2 billion via stake sale
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
03/23 FDA OKs Merck KGaA and Pfizer's avelumab for rare type of skin cancer
03/23 BeiGene, Another Beijing Venture In Cancer Therapy
03/10 Pfizer And Merck Go For An Even Longer Throw Of The Javelin
03/09 Merck KGaA's (MKGAF) CEO Stefan Oschmann on Q4 2016 Results - Earnings Call T..
03/09 Merck KGaA 2016 Q4 - Results - Earnings Call Slides
Advertisement
Financials (€)
Sales 2017 15 583 M
EBIT 2017 3 274 M
Net income 2017 1 846 M
Debt 2017 9 671 M
Yield 2017 1,22%
P/E ratio 2017 24,33
P/E ratio 2018 20,67
EV / Sales 2017 1,49x
EV / Sales 2018 1,31x
Capitalization 13 474 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 110 €
Spread / Average Target 5,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA4.69%14 491
ABBVIE INC5.03%104 810
KYOWA HAKKO KIRIN CO L..10.01%9 226
JAZZ PHARMACEUTICALS P..33.95%8 725
CONVATEC GROUP PLC14.96%6 632
MALLINCKRODT PLC-8.53%4 771
More Results